DDIT3 and diffuse large B-cell lymphoma: The available studies are substantially based on a candidate gene approach, and few polymorphisms in genes involved in the ADME of R-CHOP drugs or in immunity, inflammation and apoptotic processes have been identified as potential predictors of DLBCL outcomes [31,32].